Market Overview:
The global oligonucleotide API market is expected to grow at a CAGR of 10.8% during the forecast period from 2018 to 2030. The growth of this market can be attributed to the increasing demand for oligonucleotide-based therapeutics and rising prevalence of chronic diseases. Based on type, the global oligonucleotide API market is segmented into antisense oligonucleotides API, small interfering RNA (siRNA) API, miRNA API, CpG oligonucleotides API and others. The antisense oligonucleotides APIs segment is expected to account for the largest share of the global market in 2018. This segment is projected to grow at a CAGR of 11% during the forecast period from 2018 to 2030. This growth can be attributed to increasing demand for antisense-based therapeutics due to their ability to selectively target specific genes and proteins involved in various diseases.
Product Definition:
An oligonucleotide is a molecule composed of two or more nucleotides. Oligonucleotides are often used in molecular biology and biochemistry as probes for detecting complementary sequences of DNA or RNA, or as primers for initiating polymerase chain reactions.
Antisense Oligonucleotides API:
Antisense oligonucleotides (ASO) are synthetic, non-natural nucleic acid building blocks. They are a type of DNA aptamers that can be used in the preparation of an anti-cancer drug or as a therapy for genetic diseases. The product is expected to find application in the treatment of genetic disorders such as Gaucher's disease and Tay-Sachs disease by targeting their respective causative genes.
Small Interfering RNA (siRNA) API:
Small Interfering RNA (siRNA) API is an innovative and emerging technology that has been used in the field of research for a few years. It is now being commercialized as a novel approach to develop therapeutics with improved efficacy and potency.
Application Insights:
The pharmaceutical companies application segment accounted for the largest revenue share in 2016. The growth of this segment is attributed to the extensive usage of oligonucleotides in drug development and clinical research activities. The Contract Manufacturing Organizations (CMOs) are also anticipated to exhibit lucrative growth over the forecast period owing to their growing use in manufacturing biopharmaceutical products including vaccines, therapeutics, and diagnostic reagents.
Owing to stringent regulations related to safety & efficacy concerns, there has been a rise in demand for these products within a framework that ensures quality and stability. This has ledto an increase in applications across multiple industries such as diagnostics, therapeutics & vaccines among others which is expected drive market growth over the forecast period (2017-2030).
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of CROs and CMOs that are engaged in drug discovery & development is one of the major factors contributing to this dominance. Moreover, increasing R&D expenditure by pharmaceutical companies for drug discovery & development has also fueled growth in this region. For instance, according to an article published by Mckinsey’s Global Institute, healthcare spending increased from USD X billion (USD X per person) in 2011 to USD X billion (USD X per person) in 2015 and is expected to reach up to USD X billion by 2020 with most of it going towards R&D costs associated with new molecular entities.
Growth Factors:
- Increasing demand for nucleic acid-based drugs for the treatment of various diseases
- Growing prevalence of cancer and other genetic disorders
- Rising investments in R&D for the development of novel oligonucleotide-based therapies
- Technological advancements in oligonucleotide synthesis and delivery methods
- Growing demand from emerging markets
Scope Of The Report
Report Attributes
Report Details
Report Title
Oligonucleotide API Market Research Report
By Type
Antisense Oligonucleotides API, Small Interfering RNA (siRNA) API, MiRNA API, CpG Oligonucleotides API, Others
By Application
Contract Manufacturing Organizations (CMOs), Pharmaceutical Companies
By Companies
Jazz Pharmaceuticals, Sarepta Therapeutics, Biogen, Dynavax Technologies, Akcea Therapeutics, Alnylam Pharmaceuticals, Nitto Denko (Avecia), Ajinomoto (GeneDesign), RiboBio
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
242
Number of Tables & Figures
170
Customization Available
Yes, the report can be customized as per your need.
Global Oligonucleotide API Market Report Segments:
The global Oligonucleotide API market is segmented on the basis of:
Types
Antisense Oligonucleotides API, Small Interfering RNA (siRNA) API, MiRNA API, CpG Oligonucleotides API, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Contract Manufacturing Organizations (CMOs), Pharmaceutical Companies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Jazz Pharmaceuticals
- Sarepta Therapeutics
- Biogen
- Dynavax Technologies
- Akcea Therapeutics
- Alnylam Pharmaceuticals
- Nitto Denko (Avecia)
- Ajinomoto (GeneDesign)
- RiboBio
Highlights of The Oligonucleotide API Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Antisense Oligonucleotides API
- Small Interfering RNA (siRNA) API
- MiRNA API
- CpG Oligonucleotides API
- Others
- By Application:
- Contract Manufacturing Organizations (CMOs)
- Pharmaceutical Companies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Oligonucleotide API Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Oligonucleotide API refers to a set of tools and services that allow developers to access, manipulate, and analyze oligonucleotides. These tools can be used for research purposes or for developing applications that require the analysis of nucleic acids.
Some of the major players in the oligonucleotide api market are Jazz Pharmaceuticals, Sarepta Therapeutics, Biogen, Dynavax Technologies, Akcea Therapeutics, Alnylam Pharmaceuticals, Nitto Denko (Avecia), Ajinomoto (GeneDesign), RiboBio.
The oligonucleotide api market is expected to grow at a compound annual growth rate of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Oligonucleotide API Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Oligonucleotide API Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Oligonucleotide API Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Oligonucleotide API Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Oligonucleotide API Market Size & Forecast, 2020-2028
4.5.1 Oligonucleotide API Market Size and Y-o-Y Growth
4.5.2 Oligonucleotide API Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Antisense Oligonucleotides API
5.2.2 Small Interfering RNA (siRNA) API
5.2.3 MiRNA API
5.2.4 CpG Oligonucleotides API
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Contract Manufacturing Organizations (CMOs)
6.2.2 Pharmaceutical Companies
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Oligonucleotide API Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Oligonucleotide API Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Antisense Oligonucleotides API
9.6.2 Small Interfering RNA (siRNA) API
9.6.3 MiRNA API
9.6.4 CpG Oligonucleotides API
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Contract Manufacturing Organizations (CMOs)
9.10.2 Pharmaceutical Companies
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Antisense Oligonucleotides API
10.6.2 Small Interfering RNA (siRNA) API
10.6.3 MiRNA API
10.6.4 CpG Oligonucleotides API
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Contract Manufacturing Organizations (CMOs)
10.10.2 Pharmaceutical Companies
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Antisense Oligonucleotides API
11.6.2 Small Interfering RNA (siRNA) API
11.6.3 MiRNA API
11.6.4 CpG Oligonucleotides API
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Contract Manufacturing Organizations (CMOs)
11.10.2 Pharmaceutical Companies
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Antisense Oligonucleotides API
12.6.2 Small Interfering RNA (siRNA) API
12.6.3 MiRNA API
12.6.4 CpG Oligonucleotides API
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Contract Manufacturing Organizations (CMOs)
12.10.2 Pharmaceutical Companies
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Antisense Oligonucleotides API
13.6.2 Small Interfering RNA (siRNA) API
13.6.3 MiRNA API
13.6.4 CpG Oligonucleotides API
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Contract Manufacturing Organizations (CMOs)
13.10.2 Pharmaceutical Companies
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Oligonucleotide API Market: Competitive Dashboard
14.2 Global Oligonucleotide API Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Jazz Pharmaceuticals
14.3.2 Sarepta Therapeutics
14.3.3 Biogen
14.3.4 Dynavax Technologies
14.3.5 Akcea Therapeutics
14.3.6 Alnylam Pharmaceuticals
14.3.7 Nitto Denko (Avecia)
14.3.8 Ajinomoto (GeneDesign)
14.3.9 RiboBio
